Abstract
Results from this study support the continued use of daratumumab monotherapy in carefully selected patients who may not be candidates for more intensive combination therapies due to age, comorbidities, or prior toxicities. However, further research is needed to confirm these early observations.
Presented at Great Lakes PRC
Document Type
Poster
Publication Date
2025
Recommended Citation
Carreon, Gabrielle O. PharmD, MS, "Daratumumab monotherapy: reconsidering relapsed and refractory multiple myeloma maintenance therapy" (2025). Pharmacy Residency. 50.
https://researchrepository.parkviewhealth.org/pharmresidency/50